Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma… (NCT01170429) | Clinical Trial Compass
UnknownPhase 4
Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA)
China160 participantsStarted 2010-07
Plain-language summary
The purpose of this study is to investigate the efficacy and safety of procaterol hydrochloride with inhaled glucocorticoid in treatment patients with cough variant asthma (CVA).
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* male or female patients,18-75 years old;
* cough lasting over 3 weeks ; dry cough or with slight white mucous phlegm; cough is the main clinical symptom or the only symptom;
* without wheeze and fever;
* without the history of upper respiratory tract infection within recent two months; non-smoking or giving-up smoking for over two years;
* without rales from lung;
* no obvious abnormalities from chest X-ray;
* bronchial provocation test: positive.
Exclusion Criteria:
* patients with chronic pulmonary disease;
* patients who are allergic to ß2 receptor agonist;
* patients taking ß2 receptor agonist for long time;
* severe heart, renal and hepatic disease;
* unable to comply with the protocol;
* pregnant, breast feeding, and childbearing potential women;
* patients improper to the trial according to the investigators' judgment.
What they're measuring
1
Patient cough symptom score
Timeframe: 8 weeks
2
Therapy duration
Timeframe: 8 weeks
3
Rates of adverse events
Timeframe: 8 weeks
Trial details
NCT IDNCT01170429
SponsorShanghai Jiao Tong University School of Medicine